Biomea Fusion Quote - BMEA

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

3.61

Bid

3.61

Ask

4.20

Volume

0.00 Day's Range 0.00

3.25 52 Week Range 19.3549

Market Cap

130.822M

Previous Close

3.61

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

800,624

Shares Outstanding

36,238,687

Dividend Yield

PE Ratio

-1.12

Earnings Per Share (EPS)

-3.24

Revenue

Net Profit

-117.26M

Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.biomeafusion.com

Headquarters

Wilmington, Delaware, USA

Founded

Biomea Fusion Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BMEA. The last closing price for Biomea Fusion was US$3.61. Over the last year, Biomea Fusion shares have traded in a share price range of US$ 3.25 to US$ 19.3549.

Biomea Fusion currently has 36,238,687 shares outstanding. The market capitalization of Biomea Fusion is US$130.82 million. Biomea Fusion has a price to earnings ratio (PE ratio) of -1.12.

Form 8-K - Current report

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea...

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide...

Form S-8 - Securities to be offered to employees in employee benefit plans

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Form 8-K - Current report

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean...

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a...

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to...

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.45	-11.0837438424	4.06	4.15	3.25	645552	3.61373246	CS
4	-0.5	-12.1654501217	4.11	4.59	3.25	492497	3.97746975	CS
12	-2.75	-43.2389937107	6.36	7.5	3.25	800624	4.64076949	CS
26	-2.16	-37.4350086655	5.77	13.07	3.25	782557	7.05695872	CS
52	-13.34	-78.7020648968	16.95	19.3549	3.25	978320	8.65359404	CS
156	-2.64	-42.24	6.25	43.69	2.84	663399	14.37870647	CS
260	-16.39	-81.95	20	43.69	2.84	550477	14.26157336	CS

BMEA - Frequently Asked Questions (FAQ)

What is the current Biomea Fusion share price?

The current share price of Biomea Fusion is US$ 3.61

How many Biomea Fusion shares are in issue?

Biomea Fusion has 36,238,687 shares in issue

What is the market cap of Biomea Fusion?

The market capitalisation of Biomea Fusion is USD 130.82M

What is the 1 year trading range for Biomea Fusion share price?

Biomea Fusion has traded in the range of US$ 3.25 to US$ 19.3549 during the past year

What is the PE ratio of Biomea Fusion?

The price to earnings ratio of Biomea Fusion is -1.12

What is the reporting currency for Biomea Fusion?

Biomea Fusion reports financial results in USD

What is the latest annual profit for Biomea Fusion?

The latest annual profit of Biomea Fusion is USD -117.26M

What is the registered address of Biomea Fusion?

The registered address for Biomea Fusion is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Biomea Fusion website address?

The website address for Biomea Fusion is www.biomeafusion.com

Which industry sector does Biomea Fusion operate in?

Biomea Fusion operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VRPXVirpax Pharmaceuticals Inc	US$ 0.515 (78.26%)	7.79M
MBRXMoleculin Biotech Inc	US$ 2.10 (65.35%)	12.77M
NSTSNSTS Bancorp Inc	US$ 19.84 (56.34%)	12
NESRNational Energy Services Reunited Corporation	US$ 14.69 (55.61%)	1
ZCARZoomcar Holdings Inc	US$ 2.09 (41.22%)	1.04M
ISPOInspirato Inc	US$ 2.01 (-55.82%)	1
ELDNEledon Pharmaceuticals Inc	US$ 2.01 (-55.23%)	1
PCLAPicoCELA Inc	US$ 3.84 (-52.18%)	76.86k
FTQIFirst Trust Exchange Traded Fund VI Nasdaq BuyWrite Income ETF	US$ 11.01 (-48.26%)	3
TELATELA Bio Inc	US$ 1.51 (-41.92%)	1
CNSPCNS Pharmaceuticals Inc	US$ 0.138 (28.01%)	32.14M
MBRXMoleculin Biotech Inc	US$ 2.10 (65.35%)	12.78M
VRPXVirpax Pharmaceuticals Inc	US$ 0.5155 (78.44%)	7.8M
CYNCYNGN Inc	US$ 0.0923 (-12.10%)	3.79M
MGOLMGO Global Inc	US$ 0.8046 (-4.78%)	3.43M